- Home
- PLX vs PZC Comparison
PLX vs PZC Comparison
Compare PLX & PZC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- PZC
- Stock Information
- Founded
- PLX 1993
- PZC 2002
- Country
- PLX United States
- PZC United States
- Employees
- PLX N/A
- PZC N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- PZC Investment Managers
- Sector
- PLX Health Care
- PZC Finance
- Exchange
- PLX Nasdaq
- PZC Nasdaq
- Market Cap
- PLX 122.6M
- PZC 140.1M
- IPO Year
- PLX 1998
- PZC N/A
- Fundamental
- Price
- PLX $1.46
- PZC $6.09
- Analyst Decision
- PLX Strong Buy
- PZC
- Analyst Count
- PLX 1
- PZC 0
- Target Price
- PLX $15.00
- PZC N/A
- AVG Volume (30 Days)
- PLX 1.3M
- PZC 48.2K
- Earning Date
- PLX 08-13-2025
- PZC 01-01-0001
- Dividend Yield
- PLX N/A
- PZC 4.68%
- EPS Growth
- PLX N/A
- PZC N/A
- EPS
- PLX 0.05
- PZC N/A
- Revenue
- PLX $59,764,000.00
- PZC N/A
- Revenue This Year
- PLX $65.02
- PZC N/A
- Revenue Next Year
- PLX $57.34
- PZC N/A
- P/E Ratio
- PLX $30.21
- PZC N/A
- Revenue Growth
- PLX 0.18
- PZC N/A
- 52 Week Low
- PLX $0.82
- PZC $6.30
- 52 Week High
- PLX $3.10
- PZC $8.20
- Technical
- Relative Strength Index (RSI)
- PLX 46.02
- PZC 32.07
- Support Level
- PLX $1.36
- PZC $6.13
- Resistance Level
- PLX $1.54
- PZC $6.25
- Average True Range (ATR)
- PLX 0.08
- PZC 0.04
- MACD
- PLX 0.02
- PZC -0.01
- Stochastic Oscillator
- PLX 41.67
- PZC 5.26
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About PZC PIMCO California Municipal Income Fund III of Beneficial Interest
PIMCO CA Muni Income Fund III operates as a closed-end management investment company. The investment objective of the fund is to seek to provide current income exempt from federal and California income tax. Its portfolio of investments includes investment in different sectors such as education, healthcare, industrial and others.